Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.57 |
| ▸ | ITK | Q08881 | 4/20 | 0.56 |
| ▸ | BTK | Q06187 | 7/20 | 0.55 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945484 | 0.89 | EGFR (0.67) | EGFRITKBTKJAK2BLK | |
| SCHEMBL29534445 | 0.89 | EGFR (0.67) | EGFRITKBTKJAK2BLK | |
| SCHEMBL16391074 | 0.87 | EGFR (0.65) | EGFRITKBTKJAK2BLK | |
| SCHEMBL9945479 | 0.87 | BTK (0.65) | EGFRITKBTKMAP2K7JAK2 | |
| SCHEMBL16370708 | 0.87 | EGFR (0.73) | EGFRITKBTKCTSC | |
| SCHEMBL9946937 | 0.84 | EGFR (0.66) | EGFRITKBTK | |
| SCHEMBL2352967 | 0.84 | EGFR (0.78) | EGFRITKBTKJAK2BLK | |
| SCHEMBL9946942 | 0.83 | EGFR (0.67) | EGFRITKBTKJAK2BLK | |
| SCHEMBL9945483 | 0.82 | EGFR (0.43) | EGFRITK | |
| SCHEMBL21443612 | 0.81 | ITK (0.65) | EGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ITK 2206/4885BTK 988/4885 |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ITK 2206/4885BTK 988/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ITK 2206/4885BTK 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.